首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1463278

全球血漿分餾市場規模、佔有率、成長分析、依產品、依方法、依應用、依最終用途 - 產業預測 2024-2031

Global Plasma Fractionation Market Size, Share, Growth Analysis, By Product, By Method, By Application, By End Use - Industry Forecast 2024-2031

出版日期: 2024年04月09日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球血漿分離市場規模約為308.7億美元，預計將從2023年的334.3億美元增至2031年的632.7億美元，預測期內（2024-2031年）複合年成長率為8.3% 。

在 COVID-19 大流行期間，恢復期血漿的需求增加，因為醫生將其用作病毒感染患者的初始治療方法。例如，根據 Frontiers 2021 年 6 月的一篇論文，恢復期血漿在全球廣泛用於治療住院的 COVID-19 患者並減緩疾病進展。研究表明，恢復期血漿輸注與症狀改善和病毒清除有關，促使治療 COVID-19 患者的血漿成分需求最初激增。然而，隨著疫情的減弱和感染該病毒的人數減少，所分析的市場預計將在研究預測期內實現穩定成長。有幾個具體因素正在推動市場的擴張。其中包括免疫球蛋白在各個治療領域的使用不斷增加、老年人口的不斷擴大、罕見疾病發病率的上升以及全球血漿採集設施的激增。例如，根據世界衛生組織 2022 年 10 月的統計數據，到 2050 年，全球 60 歲以上人口的比例預計將增加近兩倍，其中很大一部分老年人口居住在低收入和中等收入國家。此外，主要市場參與者採取的各種舉措，包括產品發布、合作、併購和收購，旨在將先進的血漿分離方法和產品引入市場，預計將為市場擴張做出積極貢獻。例如，2022 年 1 月，Octapharma 獲得授權擴大 Cutaquig 在歐盟 (EU) 的使用。 Cutaquig 是一種皮下注射的人類免疫球蛋白，為許多患有遺傳性免疫缺陷的患者提供靈活的治療選擇。總體而言，預計老年人口的增加，加上罕見疾病盛行率的增加、血漿採集中心的激增以及主要市場參與者的各種舉措，預計將對預測期內的市場成長產生積極影響。然而，該行業面臨限制，例如血漿蛋白產品加工的嚴格法規、高定價和報銷課題。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2021 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率（%），2021年

主要公司簡介

CSL Behring
Grifols
Octapharma
Baxalta/Shire
Kedrion
China Biologic Products Holdings
Sanquin
Bio Products Laboratory
Japan Blood Products Organization
LFB Group
Shanghai RAAS Blood Products
Green Cross Corporation
Baxter International Inc.
Takeda Pharmaceutical Company Limited
Beijing Tiantan Biological Products
Biotest AG
China National Pharmaceutical Group Co. (Sinopharm)
GC Pharma
ADMA Biologics
Emergent BioSolutions

簡介目錄

Product Code: SQMIG35H2165

Global plasma fractionation market size was valued at around 30.87 billion in 2022 and is expected to rise from USD 33.43 billion in 2023 to reach a value of USD 63.27 billion by 2031, at a CAGR of 8.3 % over the forecast period (2024-2031).

Convalescent plasma witnessed heightened demand during the COVID-19 pandemic as doctors utilized it as an initial treatment for virus-infected patients. For example, according to a June 2021 Frontiers paper, convalescent plasma was extensively employed worldwide to treat hospitalized COVID-19 patients and mitigate disease progression. Studies have indicated that convalescent plasma transfusion is associated with improved symptomatology and virus clearance, leading to an initial surge in the need for plasma fractions to treat COVID-19 patients. However, as the pandemic waned and fewer individuals contracted the virus, the analyzed market is expected to witness steady growth over the study's forecast period. Several specific factors are fueling the expansion of the market. These include the increasing utilization of immunoglobulins across various therapeutic domains, the expanding elderly population, coupled with the rising incidence of rare diseases, and the proliferation of plasma collection facilities globally. For instance, according to WHO statistics from October 2022, the proportion of individuals worldwide aged over 60 is projected to nearly triple by 2050, with a significant portion of the elderly population residing in low- and middle-income countries. Furthermore, various initiatives undertaken by major market players, including product launches, partnerships, mergers, and acquisitions, aimed at introducing advanced plasma fractionation methods and products to the market, are expected to contribute positively to market expansion. For instance, in January 2022, Octapharma received authorization to expand the use of Cutaquig in the European Union (EU). Cutaquig, a subcutaneously administered human immunoglobulin, offers flexible therapeutic options for numerous patients with inherited immune deficiencies. Overall, the projected rise in the elderly population, coupled with an increase in the prevalence of rare diseases, the proliferation of plasma collection centers, and various initiatives by major market players, are all anticipated to positively impact market growth during the forecast period. However, the industry faces constraints such as stringent regulations governing the processing of plasma protein products, high pricing, and reimbursement challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the global plasma fractionation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Plasma Fractionation Market Segmental Analysis

The global plasma fractionation market is segmented based on product, method, application, end use, and region. By product, the market is segmented into albumin, immunoglobulins, coagulation factors, protease inhibitors. By method, the market is segmented into centrifugation, depth filtration, and chromatography. By application, the market is segmented into neurology, hematology, oncology, immunology, and pulmonology. By end use, the market is segmented into hospitals & clinics, clinical research, and others. By region, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Plasma Fractionation Market

The aging population significantly drives the plasma fractionation market. As individuals age, they become more susceptible to chronic illnesses and necessitate medical interventions, which often include plasma-derived products. This growing demographic of elderly individuals contributes to the increasing demand for plasma fractionation products as healthcare providers seek to address the healthcare needs associated with aging populations.

Restraints in the Global Plasma Fractionation Market

The high cost of plasma fractionation products poses a significant restraint on market growth. Manufacturing these products involves substantial expenses, rendering them unaffordable for certain patients and healthcare systems. This cost barrier limits access to these crucial treatments and hampers the overall growth potential of the market.

Market Trends of the Global Plasma Fractionation Market

Immunoglobulins serve as the primary treatment for various immunologic, hematologic, and neurologic conditions. Technological advancements in the past decade have led to increased diagnoses of immunological disorders. Consequently, there is a growing clinical demand for immunoglobulins, driven by the expanding genetic research aimed at defining and diagnosing immunodeficiency disorders. According to IG Living, a publication for the immune globulin (IG) community, immunoglobulins are utilized for numerous on- and off-label indications, with off-label uses comprising a significant portion, ranging from 20% to 60%, of their clinical application. Notably, the use of immunoglobulins for off-label purposes has surpassed their on-label applications in recent years. Furthermore, the prevalence of rare and autoimmune diseases, coupled with increased global research in immunology, is propelling the market's growth. According to the National Center for Advancing Translational Sciences, only a fraction of the 7,000 to 10,000 rare diseases identified have any form of treatment, indicating a vast unmet medical need. The surge in the incidence of rare disorders is contributing to the expansion of the immunoglobulin market, as these conditions necessitate ongoing treatment and management with immunoglobulin therapy.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Plasma Fractionation Market by Product

Market Overview
Albumin
Immunoglobulins
Coagulation Factors
and Protease Inhibitors

Global Plasma Fractionation Market by Method

Market Overview
Centrifugation
Depth Filtration
and Chromatography

Global Plasma Fractionation Market by Application

Market Overview
Neurology
Hematology
Oncology
Immunology
and Pulmonology

Global Plasma Fractionation Market by End Use

Market Overview
Hospitals & Clinics
Clinical Research and Others

Global Plasma Fractionation Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

CSL Behring
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxalta/Shire
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China Biologic Products Holdings
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanquin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio Products Laboratory
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Japan Blood Products Organization
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LFB Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai RAAS Blood Products
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Green Cross Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beijing Tiantan Biological Products
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biotest AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China National Pharmaceutical Group Co. (Sinopharm)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GC Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ADMA Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments